Do not take your ibuprofen at the same time as your oral semaglutide
Our 2030 estimates contemplate global penetration into the addressable type 2 diabetes and obesity markets of only 8% and 2%, respectively (from about 3% and 0.2% in 2023). Uptake would likely be greater if these drugs could be consumed in oral form rather than injected, adds the report, An oral weight loss agent would likely be well-received in the primary care setting and could alleviate pressure on supply chains
Quick Answer: GLP-1-related bloating can be reduced through smaller frequent meals, avoiding high-fat and gas-producing foods, eating slowly, gentle post-meal walking, and dose adjustment strategies under medical supervision
In those patients, addressing the underlying metabolic dysfunction first, through dietary intervention, GLP-1 therapy if indicated, or NAD+ support for cellular energy metabolism, is the clinical priority